Outlook Therapeutics, Inc. Logo

Outlook Therapeutics, Inc.

Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.

OTLK | US

Overview

Corporate Details

ISIN(s):
US69012T3059 (+1 more)
LEI:
Country:
United States of America
Address:
111 S. WOOD AVENUE, 8830 ISELIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an ophthalmic formulation of bevacizumab for the treatment of retinal diseases. The company's primary focus is on conditions such as wet age-related macular degeneration (wet AMD). Its key product, LYTENAVA™, is the first ophthalmic formulation of bevacizumab to receive Marketing Authorization from the European Commission and the UK's MHRA for wet AMD, with a commercial launch planned for the EU and UK. In the United States, ONS-5010 is an investigational drug with a Biologics License Application resubmitted to the FDA. If approved, it would be the first FDA-approved ophthalmic bevacizumab for retinal indications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Outlook Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Outlook Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Outlook Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

DiaMedica Therapeutics Inc. Logo
Developing a novel protein therapy for acute ischemic stroke and preeclampsia.
United States of America
DMAC
Diamyd Medical AB (publ) Logo
Developing precision immunotherapies to preserve insulin in autoimmune diabetes.
Sweden
DMYD
Dianthus Therapeutics, Inc. /DE/ Logo
Developing selective antibody therapies for severe autoimmune diseases.
United States of America
DNTH
Diasorin Logo
Develops immunodiagnostic and molecular diagnostic kits and systems for healthcare and research.
Italy
DIA
Disc Medicine, Inc. Logo
Developing novel therapies for patients with serious hematologic and rare blood disorders.
United States of America
IRON
DONG-A ST CO.,LTD Logo
Develops and distributes ethical drugs, medical devices, and diagnostics for global healthcare.
South Korea
170900
DongKoo Bio & Pharma Co., Ltd. Logo
Pharma leader in dermatology, developing treatments, probiotics, and investing in biotech therapies.
South Korea
006620
DongKook Life Science Co., Ltd. Logo
A pharmaceutical firm specializing in contrast media for diagnostic imaging and medical devices.
South Korea
303810
DongKookPharmaceuticalCo.,Ltd. Logo
Develops, manufactures, and distributes pharmaceuticals and healthcare products globally.
South Korea
086450
DONGSUNG PHARMACEUTICAL CO.,LTD Logo
A Korean firm making pharmaceuticals, cosmetics, and popular hair care products for over 60 years.
South Korea
002210

Talk to a Data Expert

Have a question? We'll get back to you promptly.